Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial

Kyoungmin Lee; Kyung Hun Lee; Dong Wan Kim; Jeesun Yoon; Yoon Ji Choi; Soohyeon Lee; Ju Won Kim; Kyong Hwa Park; Wonyoung Choi; Youngjoo Lee; Hyewon Ryu; Dong Hoe Koo; Yun Gyoo Lee; Hei Cheul Jeung; Min Young Lee; Namsu Lee; Myoung Joo Kang; Jieun Lee; Sook Hee Hong; Eun Joo Kang; In Hae Park

doi:10.1002/cac2.70026

Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial

Kyoungmin Lee
, Kyung Hun Lee
, Dong Wan Kim
, Jeesun Yoon
, Yoon Ji Choi
, Soohyeon Lee
, Ju Won Kim
, Kyong Hwa Park
, Wonyoung Choi
, Youngjoo Lee
, Hyewon Ryu
, Dong Hoe Koo
, Yun Gyoo Lee
, Hei Cheul Jeung
, Min Young Lee
, Namsu Lee
, Myoung Joo Kang
, Jieun Lee
, Sook Hee Hong
, Eun Joo Kang

In Hae Park

Department of Internal Medicine

Korea University
Seoul National University
National Cancer Center Korea
Chungnam National University
Kangbuk Samsung Hospital
Yonsei University
Soonchunhyang University
Inje University
The Catholic University of Korea, College of Medicine

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	841-845
Number of pages	5
Journal	Cancer Communications
Volume	45
Issue number	7
DOIs	https://doi.org/10.1002/cac2.70026
State	Published - Jul 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/cac2.70026

Cite this

Lee, K., Lee, K. H., Kim, D. W., Yoon, J., Choi, Y. J., Lee, S., Kim, J. W., Park, K. H., Choi, W., Lee, Y., Ryu, H., Koo, D. H., Lee, Y. G., Jeung, H. C., Lee, M. Y., Lee, N., Kang, M. J., Lee, J., Hong, S. H., ... Park, I. H. (2025). Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial. Cancer Communications, 45(7), 841-845. https://doi.org/10.1002/cac2.70026

@article{8ef8a609c6ef410c87364a1c3159f6d2,

title = "Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial",

author = "Kyoungmin Lee and Lee, \{Kyung Hun\} and Kim, \{Dong Wan\} and Jeesun Yoon and Choi, \{Yoon Ji\} and Soohyeon Lee and Kim, \{Ju Won\} and Park, \{Kyong Hwa\} and Wonyoung Choi and Youngjoo Lee and Hyewon Ryu and Koo, \{Dong Hoe\} and Lee, \{Yun Gyoo\} and Jeung, \{Hei Cheul\} and Lee, \{Min Young\} and Namsu Lee and Kang, \{Myoung Joo\} and Jieun Lee and Hong, \{Sook Hee\} and Kang, \{Eun Joo\} and Park, \{In Hae\}",

year = "2025",

month = jul,

doi = "10.1002/cac2.70026",

language = "English",

volume = "45",

pages = "841--845",

journal = "Cancer Communications",

issn = "2523-3548",

publisher = "American Association for the Advancement of Science",

number = "7",

}

Lee, K, Lee, KH, Kim, DW, Yoon, J, Choi, YJ, Lee, S, Kim, JW, Park, KH, Choi, W, Lee, Y, Ryu, H, Koo, DH, Lee, YG, Jeung, HC, Lee, MY, Lee, N, Kang, MJ, Lee, J, Hong, SH, Kang, EJ & Park, IH 2025, 'Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial', Cancer Communications, vol. 45, no. 7, pp. 841-845. https://doi.org/10.1002/cac2.70026

TY - JOUR

T1 - Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors

T2 - KCSG AL20-17/KM23 trial

AU - Lee, Kyoungmin

AU - Lee, Kyung Hun

AU - Kim, Dong Wan

AU - Yoon, Jeesun

AU - Choi, Yoon Ji

AU - Lee, Soohyeon

AU - Kim, Ju Won

AU - Park, Kyong Hwa

AU - Choi, Wonyoung

AU - Lee, Youngjoo

AU - Ryu, Hyewon

AU - Koo, Dong Hoe

AU - Lee, Yun Gyoo

AU - Jeung, Hei Cheul

AU - Lee, Min Young

AU - Lee, Namsu

AU - Kang, Myoung Joo

AU - Lee, Jieun

AU - Hong, Sook Hee

AU - Kang, Eun Joo

AU - Park, In Hae

PY - 2025/7

Y1 - 2025/7

UR - https://www.scopus.com/pages/publications/105002400713

U2 - 10.1002/cac2.70026

DO - 10.1002/cac2.70026

M3 - Letter

C2 - 40211931

AN - SCOPUS:105002400713

SN - 2523-3548

VL - 45

SP - 841

EP - 845

JO - Cancer Communications

JF - Cancer Communications

IS - 7

ER -

Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial

UN SDGs

Access to Document

Other files and links

Cite this